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Characterization of Mutations in the CPO Gene in British Patients
Demonstrates Absence of Genotype-Phenotype Correlation and Identifies
Relationship between Hereditary Coproporphyria and Harderoporphyria
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Vasco Da Silva,1 Jean-Charles Deybach,1 and George H. Elder2
1Centre Franc¸ais des Porphyries and INSERM U409, Universite´ Paris VII, Hoˆpital Louis Mourier, Colombes, France; and 2Department of
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Hereditary coproporphyria (HCP) is the least common of the autosomal dominant acute hepatic porphyrias. It
results from mutations in the CPO gene that encodes the mitochondrial enzyme, coproporphyrinogen oxidase. A
few patients have also been reported who are homoallellic or heteroallelic for CPO mutations and are clinically
distinct from those with HCP. In such patients the presence of a specific mutation (K404E) on one or both alleles
produces a neonatal hemolytic anemia that is known as “harderoporphyria”; mutations on both alleles elsewhere
in the gene give rise to the “homozygous” variant of HCP. The molecular relationship between these disorders and
HCP has not been defined. We describe the molecular investigation and clinical features of 17 unrelated British
patients with HCP. Ten novel and four previously reported CPOmutations, together with three previously unrecog-
nized single-nucleotide polymorphisms, were identified in 15 of the 17 patients. HCP is more heterogeneous than
other acute porphyrias, with all but one mutation being restricted to a single family, with a predominance of
missense mutations (10 missense, 2 nonsense, 1 frameshift, and 1 splice site). Of the four known mutations, one
(R331W) has previously been reported to cause disease only in homozygotes. Heterologous expression of another
mutation (R401W) demonstrated functional properties similar to those of the K404E harderoporphyria mutation.
In all patients, clinical presentation was uniform, in spite of the wide range (1%–64%) of residual coproporphyr-
inogen oxidase activity, as determined by heterologous expression. Our findings add substantially to knowledge of
the molecular epidemiology of HCP, show that single copies of CPO mutations that are known or predicted to
cause “homozygous” HCP or harderoporphyria can produce typical HCP in adults, and demonstrate that the
severity of the phenotype does not correlate with the degree of inactivation by mutation of coproporphyrinogen
oxidase.
Introduction
The 14-kb human CPO gene on chromosome 3q11.2
contains seven exons that encode the mitochondrial
enzyme, coproporphyrinogen oxidase (CPOX) (EC
1.3.3.3), which catalyses the stepwise oxidative decar-
boxylation of the heme precursor, coproporphyrinogen
III, to protoporphyrinogen IX via a tricarboxylic inter-
mediate known as “harderoporphyrinogen” (Elder et al.
1978; Delfau-Larue et al. 1994). Mutations in the CPO
gene cause three clinically distinct disorders: hereditary
coproporphyria (HCP [MIM 121300]), its homozygous
variant, and harderoporphyria (Nordmann and Dey-
bach 1990; Kappas et al. 1995; Martasek 1998). HCP
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is the least common of the three autosomal dominant
acute porphyrias. As in the others—acute intermittent
porphyria (AIP) and variegate porphyria (VP)—clinical
penetrance is low, and symptoms are very rare before
puberty. Patients almost always present with an acute
neurovisceral crisis, often provoked by drugs, alcohol,
or endocrine factors (Brodie et al. 1977; Kuhnel et al.
2000). If skin lesions caused by photosensitization by
porphyrins are absent, as occurs in ∼70% of patients,
HCP is clinically indistinguishable from AIP. If they are
present, HCP resembles VP, although in the latter con-
dition ∼70% of patients have only skin lesions (Kirsch
et al. 1998; Whatley et al. 1999a). Presentation with
skin lesions alone is uncommon among patients with
HCP; the few cases reported have usually been associ-
ated with hepatobiliary dysfunction (Brodie et al. 1977;
Hawk et al. 1978; Martasek 1998). In contrast, the very
rare homozygous form of HCP presents in childhood
with skin lesions (Grandchamp et al. 1977; Martasek et
al. 1994b; Doss et al. 1999). Harderoporphyria is char-
acterized by neonatal hemolytic anemia, sometimes ac-
Lamoril et al.: Genotype-Phenotype Correlation in HPC 1131
companied by skin lesions and accumulation of harder-
oporphyrin in feces (Nordmann et al. 1983; Lamoril et
al. 1995; Lamoril et al. 1998). All affected individuals
described to date have been homoallelic or heteroallelic
for the same missense mutation in theCPO gene (K404E
in exon 6), suggesting that disruption of this region
of CPOX impairs the second stage of the conversion
of coproporphyrinogen III to protoporphyrinogen IX
(Lamoril et al. 1998). Missense mutations of this region
of exon 6 have not been described in HCP.
Detection of asymptomatic affected individuals—so
they can be advised to avoid factors that provoke acute
attacks, and so they can receive prompt treatment if an
attack occurs—is an important part of the management
of HCP. Asymptomatic affected individuals can be de-
tected at any stage of life by measuring the level of
CPOX activity in lymphocytes, which is 50% of the
mean level in control subjects (Nordmann and Deybach
1990; Martasek 1998). After the age of 7 years, asymp-
tomatic affected individuals can be identified by dem-
onstration of an increased coproporphyrin isomer III:I
ratio in feces (Blake et al. 1992; Kuhnel et al. 2000).
Unfortunately, these methods are technically complex,
imprecise, or insensitive. Mutational analysis has po-
tential advantages but, because of the rarity of HCP,
has been applied to only a few families from five coun-
tries; mutations have been identified in 17 families (Del-
fau-Larue et al. 1994; Fujita et al. 1994; Daimon et al.
1997; Lamoril et al. 1997; Schreiber et al. 1997; Susa
et al. 1998; Rosipal et al. 1999; also see Human Gene
Mutation Database). The extent of allelic heterogeneity,
the distribution and functional expression of mutations
within the CPO gene, and genotype-phenotype corre-
lations have yet to be studied in a large, unselected
group of patients from a single country. We report an
investigation of the CPO gene in 17 apparently un-
related patients from the United Kingdom.
Patients and Methods
Patients
We studied 17 apparently unrelated patients with
HCP who presented sequentially for confirmation of di-
agnosis and/or for family investigation. Thirteen patients
had a current or past attack of acute porphyria; in two
of these, skin lesions were present during the acute
attack. Four patients had never had symptoms of por-
phyria but had a family history of porphyria. Three of
the four came from families in which at least one member
was known to have overt HCP (including a large family
described by Andrews et al. [1984]). One family had
never had symptoms, the proband having been detected
during routine urine testing for another disease. In ad-
dition, samples for mutational analysis were obtained
from 29 asymptomatic relatives from eight families. The
diagnosis was established by measurement of fecal por-
phyrin: total fecal porphyrin concentrations were 360–
3,649 nmol/g dry wt (mean 2,184 nmol/g dry wt vs.
!200 nmol/g dry wt in normal subjects), with copro-
porphyrin accounting for 180% of the total porphyrin.
Coproporphyrin isomer III:I ratios, measured in nine
patients, were 23–87 (mean 36 vs. !1.4 in unaffected
subjects). VP was excluded by fluorescence-emission
spectroscopy of plasma (Poh-Fitzpatrick 1980). Fecal co-
proporphyrin isomer ratios were measured in six asymp-
tomatic family members who were found, by use of
mutational analysis, to be affected. The mode of pre-
sentation was recorded for all symptomatic family mem-
bers. Unrelatedness was determined by family inquiries;
none of the patients were known to be related. Patients
resided in various locations throughout the United King-
dom; all patients were white.
Identification of Mutations
DNA was extracted from peripheral blood leukocytes.
Exons 1–7 of the CPO gene, along with 50–150 bp of
their flanking regions, were amplified by means of the
primers and conditions described elsewhere (Rosipal et
al. 1999) and were screened for mutations by denaturing
gradient gel electrophoresis (DGGE). Regions showing
abnormal patterns were sequenced to identify mutations
and polymorphisms. When no abnormality was detected
by DGGE, the gene was sequenced.
For DNA sequencing, the CPO gene was amplified
with primers different from those used for DGGE anal-
ysis (Rosipal et al. 1999). DNA fragments were purified
with the Qiaquick PCR purification kit (Qiagen) and
were directly sequenced using the Thermo Sequenase
radiolabeled dye terminator (a-33[P] dideoxyribonucleo-
tide triphosphate) cycle sequencing kit (Amersham Life
Science). The presence of mutations was confirmed by
sequencing of both DNA strands of amplified DNA.
Construction and Prokaryotic Expression of Normal
and Mutated Human CPOX cDNA
Normal human cDNA was expressed using the pGEX-
2T expression vector (Pharmacia Biotech) in the recom-
binant bacteria Escherichia coliDH5a, as described else-
where (Lamoril et al. 1998). Site-directed mutagenesis
was performed using normal cloned CPOX cDNA
(pGEX-2T:CPOX) as the template. We used the Trans-
former site-directed mutagenesis kit (Clontech Labora-
tories), as described elsewhere (Rosipal et al. 1999). The
entire sequence of each mutated plasmid was verified by
sequencing.
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485ArC Q162P Present study
511GrA D171N Present study
2:
601GrA E201K Schreiber et al. 1997
607GrA A203T Present study
4:
877GrA A293T Present study
916CrT Q306X Rosipal et al. 1999
923GrT G308V Present study
5:




1171CrT R391W Present study
6:
1201CrT R401W Present study
1276CrT R426X Present study
1277GrA Exon 6 skipping Delfau-Larue et al. 1994
7:
1339CrT R447C Present study
Figure 1 Localization of all mutations identified in CPO gene.
Exons are represented by rectangles and are numbered 1–7. Filled
rectangles indicate protein coding, and unfilled rectangles indicate un-
translated sequences. The mutations reported in this study of patients
in the United Kingdom are depicted above the diagram, and the mu-
tations reported elsewhere are depicted below the diagram (Delfau-
Larue et al. 1994; Fujita et al. 1994; Martasek et al. 1994b; Lamoril
et al. 1995; Daimon et al. 1997; Lamoril et al. 1997, 1998; Schreiber
et al. 1997; Susa et al 1998; Doss et al. 1999; Rosipal et al. 1999). ∇
p frameshift ; ● p missense;  p nonsense; O p splice mutation;
H p harderoporphyrinogen overproduction, found in R401W and
K404E mutations.
Other Methods
The recombinant bacteria (E. coliDH5a) were grown,
and CPOX activities of control and mutant enzymes
were determined in bacterial lysates, as described else-
where (Lamoril et al. 1995). Specific activity was ex-
pressed as the mean of two duplicate experiments. Fecal
porphyrins were quantified (Lockwood et al. 1985), and
coproporphyrin isomer ratios were determined (Blake et
al. 1992) by standard methods; fluorescence-emission
spectroscopy of plasma was performed as described else-
where (Long et al. 1993).
Phylogenetic Analysis
Protein sequences were obtained from SwissProt, and
the alignment of the protein sequences was made with
Clustal W software (Thompson et al. 1994). Phyloge-
netic reconstructions were generated by using the neigh-
bor-joining method in the Phylogeny Inference Package
(PHYLIP, version 3.5c) (Felsenstein et al. 1989) with
a Kimura two-parameter distance matrix program
(PROTDIST and NEIGHBOR). Nonsynonymous phy-
logenetic reconstruction was generated with a Kimura
formula (PROTDIST). A consensus phylogenetic tree
was elaborated with the program CONSENSE.
Polymorphisms
After informed consent was obtained, the frequencies
of known and suspected single-nucleotide polymor-
phisms (SNPs) in the CPO gene were determined by
studying 84 white families who did not have porphyria.
The families were drawn from the Centre d’Etude du
Polymorphisme Humain (Paris), and frequencies were
determined by means of direct sequencing, restriction-
enzyme digestion, or DGGE.
Numbering System
Nucleotides are numbered according to the cDNA
sequence derived from the CPO genomic sequence
(Delfau-Larue et al. 1994), in which the A of the ATG
initiation codon is numbered as 1. Comparison of the
sequence of the CPO gene (Delfau-Larue et al. 1994)
with cDNA sequences (Taketani et al. 1994) revealed
that the first in-frame AUG codon lies within the first
exon, 300 bp upstream from the putative initiating co-
don described elsewhere (Martasek et al. 1994a; Take-
tani et al. 1994). CPO mutations reported in 1994–95
that were numbered from the downstream AUG have
been renumbered here: for example, R231W and K304E
become R331W and K404E, respectively.
Results
Identification of Mutations
Initially, exons 2–7 and their flanking regions, the 3′
part of exon 1 and one-fifth of the 3′ noncoding se-
quence, were amplified from genomic DNA from all 17
unrelated patients with HCP. Amplified fragments were
screened by DGGE, and any that showed abnormal pat-
terns were sequenced. The promoter, nonanalyzable
regions of exon 1, and the noncoding sequence of exon
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CPO/sense 18,460 100 11
CPO/antisense 789 … 6
Empty plasmid 728 … 9
CPO-Q162P 1,786 6 10
CPO-D171N 6,595 33 5
CPO-E201K 969 1 15
CPO-A203T 6,812 34 7
CPO-A293T 5,930 29 8
CPO-G308V 7,730 39 6
CPO-R331Wd 6,394 32 9
CPO-R391W 4,710 22 12
CPO-R401W 11,970 63e 44e
CPO-R447C 3,240 14 9
a Expression vector: pGEX-2T.
b Specific activity was expressed in pmol of pro-
toporphyrin/h/mg protein at 37C, as mean of two
duplicate experiments (see text for formula used to
calculate residual activity).
c Overall activity is shown as percent of wild-type
activity.
d Previously reported in homozygous HCP (Mar-
tasek et al. 1994b).
e Substantial accumulation of harderoporphyrin
(see fig. 3B) similar to that observed in the K404E
mutation causing harderoporphyria: residual activity
66%, with 30% of harderoporphyrin (Lamoril et al.
1998; C. Martin, personal communication).
7 were directly sequenced. This approach identified 10
novel and 4 previously reported mutations in 15 patients
(table 1). All mutations except one (1277 GrA, which
was previously identified in a French patient [Delfau et
al. 1994]) were restricted to a single family; no base
change was detected in the two remaining patients, de-
spite DGGE analysis and sequencing of all exons, their
flanking regions, and 530 bp upstream from the major
transcriptional sites (Delfau-Larue et al. 1994). Major
deletions were excluded by showing that each patient
was heterozygous for at least one intragenic SNP. This
method of mutational analysis therefore detected mu-
tations in 15 of 17 patients, giving a sensitivity of 88%
(95% confidence interval 70%–99%). Mutations were
present in all exons except exon 3, with no exon having
13 mutations (fig. 1); 10 mutations (71%) were mis-
sense, 2 (14%) produced stop codons, 1 changed an
invariant nucleotide at the splice donor site of exon 6,
and 1 (1133delC) produced a frameshift leading to a
stop codon (table 1; fig. 1).
A total of 29 asymptomatic relatives of 8 patients were
screened for the presence of the appropriate mutation.
Mutations were present in 15 of these relatives. Among
the affected relatives who provided fecal samples, fecal
porphyrin concentrations were 112–261 nmol/g dry wt
(coproporphyrin isomer III/I ratio 1.5:2.2) in three
adults and were 58–101 nmol/g dry wt (isomer ratio
0.7:2.4) in three children aged 7–9 years.
Heterologous Expression of Mutations
To further characterize CPO missense mutations,
pGEX-2T: CPO expression vectors were constructed for
each mutant allele and expressed in E. coli. Specific ac-
tivity was expressed in pmol of protoporphyrin/h/mg
protein at 37C, as mean of two duplicate experiments.
Residual activity was determined by the formula
{100# [SA SA ]}(EP) ,[ ]SA(CPO:sense)SA(EP)
where SA(EP) indicates specific activity for empty plas-
mid. Table 2 shows that the CPOX activities of the mu-
tant proteins, determined by measuring protoporphy-
rin(ogen) formation, were 1%–63% of wild-type activ-
ity, with all mutations except one decreasing activity by
 60%. Protoporphyrin(ogen) was the main reaction
product in all cases. However, one mutation (R401W)
also caused substantial accumulation (44%) of the tri-
carboxylic intermediate harderoporphyrinogen (table 3;
fig. 3). Analysis of fecal porphyrins from the patient with
this mutation showed no significant accumulation of
harderoporphyrin (fig. 3) and a pattern indistinguishable
from that of other patients with HCP.
Phylogenetic analysis of amino acid sequences for
CPOX showed a large distance between bacteria, yeast,
plants, and mammals (fig. 2A). Four mutations (D171N,
E201K, R391W, and R401W) alter residues in regions
of the enzyme that are conserved throughout evolution
(fig. 2B). Other mutations are in regions that are less
highly conserved or are conserved only between mam-
mals (fig. 2B). There was no close correlation between
degree of conservation and effect on activity.
Phenotype-Genotype Relationship
Of the 15 patients in whom mutations were identified,
11 had clinically overt HCP; 3 patients had a first-degree
relative with overt disease, and 1 patient was from a
family with no clinical manifestations of HCP. Table 3
compares the mode of presentation of the 14 probands
who had overt HCP with that of other patients with
HCP in whom CPO mutations have been identified. The
data confirm that HCP resembles AIP in being charac-
terized mainly by acute neurovisceral attacks (Brodie et
al. 1977); 4 of the patients we studied were originally
considered to have AIP.
Table 3 shows the relationship between mode of pre-
sentation and type of mutation. Truncating mutations
(frameshift, nonsense, and splice site) or missense mu-
tations are not associated with a particular mode of pre-
Figure 2 A, Phylogenetic tree of amino acid sequences for CPOX. PHYLIP software (Phylogeny Inference Package, version 3.5c) was
used to draw the phylogenetic tree and evaluate the protein sequence distance, using the protein sequence parsimony method (Felsenstein 1989).
The reference in brackets indicates the SwissProt accession number of the protein sequence. The numbers above the lines indicate the relative
distance between species. B, Comparison of amino acid sequences deduced from nucleotide sequences of human (HS), mouse (MM), Sacchar-
omyces cerevisiae (SC), E. coli (EC), Salmonella typhimurium (ST), soybean (GM), Pseudomonas aeruginosa (PS), common tobacco (Nicotiana
tabacum [TB]), barley (Hordeum vulgare [HO]), and Synechocystis species (SY). The alignment of the sequences was made with Clustal W
software (Thompson et al. 1994). Asterisks indicate identical amino acids. Diamonds indicate similar amino acids. Point mutations are represented
above the human sequence. The number indicates the position of the amino acid in the human sequence.
Lamoril et al.: Genotype-Phenotype Correlation in HPC 1135
Table 3
HCP Clinical Features and Type of Mutation













Acute attack only 11 (73%) 10 (77%) 13 (81%) 2 (67%) 6 (67%)
Skin lesions only 0 (0%) 1 (8%) 0 (0%) … 1 (11%)
Both together 4 (27%) 2 (15%) 3 (19%) 1 (33%) 2 (22%)
a At presentation, in the index case from 28 unrelated families. Differences between groups are not significant.
b Data are from Delfau-Larue et al. 1994; Lamoril et al. 1995, 1997, 1998; and Rosipal et al. 1999.
Figure 3 A, Coproporphyrin III/I ratio in samples of feces from
the patient with the R401W heterozygous mutation. B,High-perform-
ance liquid chromatography of porphyrins in vitro from expression
studies of this R401W mutation in E. coli. CI p coproporphyrin I;
CIII p coproporphyrin III; P p protoporphyrin; H p harderopor-
phyrin; C p coproporphyrin.
sentation ( ; ). In two families, differ-2x p 4.31 Pp .09
ent missense mutations gave rise, in different relatives,
to more than one type of presentation.
Four patients had mutations that were found, by het-
erologous expression, to decrease CPOX activity to
33%–39% of the level in control subjects. The mode of
presentation in these patients (three had acute attacks
only; one had an acute attack with skin lesions) did not
differ from the mode of presentation in those with trun-
cating mutations likely to lead to no residual activity
(three had acute attacks only; two had acute attacks with
skin lesions).
SNPs
Three SNPs, in addition to the five SNPs reported
elsewhere (Martasek et al. 1994b; Rosipal et al. 1999),
were identified (table 4). All eight SNPs found in the
population that we studied gave abnormal patterns on
DGGE, thereby facilitating screening of sufficient sub-
jects to establish allele frequencies (table 2). The three
novel SNPs were as follows: a CrT transition in exon
5 at nucleotide position 1054, which predicted substi-
tution R351C (frequencies of .97 for allele C and .03
for allele T, with 5.8% observed heterozygosity); an
ArC transversion 159 bp downstream from the last base
of stop codon (X159A/C) in exon 7 (frequencies of
.68 for allele A and .32 for allele C, with 43.5% observed
heterozygosity); and an ArG transition 928 bp down-
stream of the last base of stop codon (X928A/G) in
exon 7 (frequencies of .69 for allele A and .31 for allele
G, with 42.8% observed heterozygosity) (table 4).
Discussion
Using DGGE and direct sequencing, we have identified
mutations in the CPO genes of 15 of 17 unrelated British
patients with HCP (table 1). Both patients in whom mu-
tations were not identified had an unequivocal diagnosis
of HCP. Complete deletions of the CPO gene were ex-
cluded by showing that both patients were heterozygous
for at least one intragenic SNP. It is probable that the
causative mutations either lie outside the regions that
we sequenced or are partial deletions or insertions not
detected by our PCR-based methods.
Of the 14 mutations in the patients with HCP de-
scribed here, 10 are novel, bringing the total number of
mutations reported in HCP to 27 (table 1; fig. 1) (Del-
fau-Larue et al. 1994; Fujita et al. 1994; Daimon et al.
1997; Lamoril et al. 1997; Schreiber et al. 1997; Susa
et al. 1998; Rosipal et al. 1999), whereas a further 5
mutations have been identified in homozygous patients
with HCP (Martasek et al. 1994b; Doss et al. 1999) or
harderoporphyria (Lamoril et al. 1995, 1998). Eight of
the novel mutations are missense and are located in GC-
rich regions containing CpG dinucleotides known to be
hot spots for mutation (Cooper and Krawczak 1993).
The probable functional importance of the mutated
amino acids is indicated by the finding that all are con-
served between species (fig. 2B), and four of the eight
residues are highly conserved throughout evolution, de-
spite the large distance between bacterial, plant, yeast,
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Table 4
Polymorphisms Reported in the Human CPO Gene
Region and Sequence
Modification Allele Frequency References
Promoter:
—142 C/Ga .69 C/.31 G Rosipal et al. 1999
Exon 4:
814 A/C .80 A/.20 C Martasek et al. 1994a
880 G/A .70 G/.30 A Martasek et al. 1994b
Exon 5:
990 G/A .75 G/.25 A Martasek et al. 1994b
1054 C/T .97 C/.03 T Present study
Exon 7:
X159 A/Cb .68 A/.32C Present study
X574 del ATTCTTc .85 undel/.15 del Rosipal et al. 1999
X928 A/Gd .69A/.31G Present study
a Numbering according to the first base of transcription initiation
site (Delfau-Larue et al. 1994).
b At position stop codon 159.
c At position stop codon 574.
d At position stop codon 928.
and mammalian CPOXs that is revealed by phylo-
genetic analysis (fig. 2A). Heterologous expression in E.
coli of these missense mutations showed that all de-
creased protoporphyrinogen IX formation by 160%
(table 2). The other two novel mutations introduce pre-
mature stop codons (table 1) and are likely to abolish
CPOX activity, primarily by accelerating mRNA decay
(Culbertson 1999).
Previous studies of mutations in patients with typical
HCP have not revealed any relationship between this
disorder and other clinically distinct conditions caused
by CPO mutations. Here we show that a mutation
(R331W), previously identified only in homozygous pa-
tients with HCP (Martasek et al. 1994b) and having
sufficient residual activity (table 2) to support life, can
cause overt HCP in a heterozygote. This finding con-
trasts with data from mutational analysis of homozy-
gous VP, in which there is as yet no evidence that mu-
tations that preserve significant protoporphyrinogen
oxidase activity produce symptoms in heterozygotes
(Kirsch et al. 1998; Roberts et al. 1998; ), but resembles
the relationship between AIP and its homozygous
counterpart, in which the same mutations are found in
both conditions (Elder 1997).
More unexpectedly, a mutation (R401W) that we
identified in a patient with HCP was found, by heter-
ologous expression, to impair decarboxylation of hard-
eroporphyrinogen in a pattern indistinguishable from
that shown by a neighboring mutation (K404E) that,
in homozygotes or compound heterozygotes, causes
harderoporphyria (Lamoril et al. 1998) (table 2; fig.
3B). Of the 16 missense mutations in the CPO gene
that have been expressed in vitro, these are the only two
that mainly affect the second decarboxylation reaction
during the conversion of coproporphyrinogen III to pro-
toporphyrinogen IX (Martasek et al. 1997; Rosipal et
al. 1999) (table 2). Both mutations lie in a highly con-
served region of CPOX (fig. 2B) that may form part of
its single catalytic site (Lamoril et al. 1998). Our data
support the hypothesis that the short region around
R401–K404 is important for catalysis of the oxidative
decarboxylation of harderoporphyrinogen. There is ev-
idence that this intermediate remains adjacent to the
catalytic site during the conversion of coproporphyrino-
gen III to protoporphyrinogen IX (Elder et al. 1978).
The R401–K404 region may be important in preventing
diffusion of harderoporphyrinogen away from the cat-
alytic site during the sequential reaction.
The patient described here who had the R401W mu-
tation trans to a normal allele had typical HCP without
the hemolytic anemia or increased fecal excretion of
harderoporphyrin that characterizes harderoporphyria
in adults (fig. 3A) (Lamoril et al. 1998). Similarly, those
asymptomatic parents of harderoporphyric patients
who were heterozygous for the K404E mutation had a
fecal porphyrin excretion pattern identical to that found
in patients with HCP (Lamoril et al. 1998; C. Martin,
personal communication). Our finding that a single
copy of a gene carrying a mutation in this region (a
mutation that is functionally indistinguishable, by het-
erologous expression in vitro, from the harderoporphyr-
ia mutation) strongly suggests that K404E heterozy-
gotes also may develop acute attacks of porphyria and
should therefore be managed in the same way as indi-
viduals with clinically latent HCP. Still to be determined
is the mechanism by which CPOX from the normal
allele produces a pattern of porphyrin excretion in these
heterozygotes that is typical of HCP rather than hard-
eroporphyria or is intermediate between these two con-
ditions. Human CPOX is a 76-kD protein that is active
as a homodimer in the mitochondrial intermembrane
space (Martasek et al. 1997). It is possible that the
R401W and K404E mutations impair dimerization or
the function of mutant-normal heterodimers so that ac-
tivity is decreased to the levels ∼50% of normal that
are observed in heterozygotes (Lamoril et al. 1998).
Our findings also reveal differences between the pat-
tern of mutations in HCP and in other acute hepatic
porphyrias. Only one of the mutations that we identified
(1277GrA, which was previously reported in a Czech
family [Delfau-Larue et al. 1994]) was present in more
than one family. The least common of the acute por-
phyrias in the United Kingdom thus shows more allelic
heterogeneity than either of the other two, AIP (Whatley
et al. 1999b) and VP (Whatley et al. 1999a). Mutations
were spread throughout the gene (fig. 1), unlike mu-
tations in AIP (in which 60% of mutations are clustered
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Figure 4 Clinical features in acute hepatic porphyrias in British
patients.
in three exons of the HMBS gene [Puy et al. 1997;
Whatley et al. 1999b]), and a higher proportion (72%
of the patients reported here [table 1]) are missense than
in AIP or VP (Puy et al. 1997; Whatley et al. 1999a,
1999b).
The probands of all the families we studied presented
with acute attacks of porphyria, except for one family
in which latent HCP was discovered fortuitously by
urine testing. Skin lesions, when present (table 3), were
a minor feature. This uniformity of presentation adds
to previous evidence (Brodie et al. 1977; Kuhnel et al.
2000) that the clinical characteristics of HCP are closer
to those of AIP than to those of other mixed porphyria
(e.g., VP or porphyria cutanea tarda [PCT]) (fig. 4).
Neither the type of mutation (table 3) nor the extent of
inactivation of CPOX (table 2), as assessed by heter-
ologous expression in E. coli, influenced the mode of
presentation to any major extent. The wide range of
residual activity in vitro (table 2) was unexpected, be-
cause levels of CPOX activity in cells from patients with
latent or overt HCP are ∼50% of normal (Elder et al.
1976; Grandchamp and Nordmann 1977; Grandchamp
et al. 1996). This discrepancy may be explained, at least
for some mutations, by the presence of factors in human
cells that further decrease activity by affecting enzyme
processing or stability.
In conclusion, this study highlights differences be-
tween the molecular epidemiology of HCP and that of
other autosomal dominant acute porphyrias, demon-
strates that heterozygotes for mutations previously
known to cause only homozygous HCP or hardero-
porphyria may develop clinically overt HCP, shows that
there is no major correlation between genotype and se-
verity of disease in HCP, and adds to the evidence that
a few amino acid residues in exon 6 determine the ef-
ficiency of decarboxylation of harderoporphyrinogen.
Acknowledgments
This work was supported by grants from INSERM (U409)
and Universite´ Paris VII.
Electronic-Database Information




Human Gene Mutation Database,http://www.uwcm.ac.uk/
uwcm/mg/hgmd0.html (for mutations in CPO gene)
Online Mendelian Inheritance in Man (OMIM), http://www
.ncbi.nlm.nih.gov/Omim (for HCP [MIM 121300])
Phylogeny Inference Package, http://evolution.genetics.
washington.edu/phylip.html
References
Andrews J, Erdjument H, Nicholson DC (1984) Hereditary
coproporphyria: incidence in a large English family. J Med
Genet 21:341–349
Blake D, McManus J, Cronin V, Ratnaike S (1992) Fecal
coproporphyrin isomers in hereditary coproporphyria. Clin
Chem 38:96–100
Brodie MJ, Thompson GG, Moore MR, Beattie AD, Goldberg
A (1977) Hereditary coproporphyria: demonstration of the
abnormalities in haem biosynthesis in peripheral blood. Q
J Med 46:229–241
Cooper DN, Krawczak M (1993) Human gene mutation. BIOS
Scientific, Oxford
Culbertson MR (1999) RNA surveillance: unforeseen conse-
quences for gene expression, inherited genetic disorders and
cancer. Trends Genet 15:74–80
Daimon M, Gojyou E, Sugawara M, Yamatani K, Tominaga
M, Sasaki H (1997) A novel missense mutation in exon 4
of the human coproporphyrinogen oxidase gene in two
patients with hereditary coproporphyria. Hum Genet 99:
199–201
Delfau-Larue MH, Martasek P, Grandchamp B (1994) Co-
proporphyrinogen oxidase: gene organization and descrip-
tion of a mutation leading to exon skipping. Hum Mol Genet
3:1325–1330
Doss MO, Gross U, Lamoril J, Kranl C, Jacob K, Doss M, Da
Silva V, Freesemann AG, Deybach JC, Sepp, Nordamnn Y
(1999) Compound heterozygous hereditary coproporphyria
with fluorescing teeth. Ann Clin Biochem 36:680–682
Elder GH (1997) Hepatic porphyrias in children. J Inherit Me-
tab Dis 20:237–246
Elder GH, Evans JO, Jackson JR, Jackson AH (1978) Factors
determining the sequence of oxidative decarboxylation of
the 2- and 4-propionate substituents of coproporphyrinogen
III by coproporphyrinogen III oxidase in rat liver. Biochem
J 169:215–223
Elder GH, Evans JO, Thomas N (1976) The primary enzyme
defect in hereditary coproporphyria. Lancet 2:1217–1219
1138 Am. J. Hum. Genet. 68:1130–1138, 2001
Felsenstein J (1989) Phylip: Phylogeny inference package (ver-
sion 3.2). Cladistic 5:164–166
Fujita H, Kondo M, Taketani S, Nomura N, Furuyama K,
Akagi R, Nagai T, Terajima M, Galbraith RA, Sassa S (1994)
Characterization and expression of cDNA encoding copro-
porphyrinogen oxidase from a patient with hereditary co-
proporphyria. Hum Mol Genet 10:1807–1810
Grandchamp B, Nordmann Y (1977) Decreased lymphocyte
coproporphyrinogen III oxidase activity in hereditary co-
proporphyria. Biochem Biophys Res Commun 74:1089–
1095
Grandchamp B, Phung N, Nordmann Y (1977) Homozygous
case of hereditary coproporphyria. Lancet 2:1348
Grandchamp B, Puy H, Lamoril J, Deybach JC, Nordmann Y
(1996) Molecular hepatology: molecular pathogenesis of he-
patic acute porphyrias. J Gastroenterol Hepatol 11:1046–
1052
Hawk JLM, Magnus IA, Parkes A, Elder GH, Doyle M (1978)
Deficiency of hepatic copro-porphyrinogen oxidase in he-
reditary coproporphyria. J R Soc Med 71:775–777
Kappas A, Sassa S, Galbraith RA, Nordmann Y (1995) The
porphyrias. In: Scriver CR, Beaudet AL, Sly WS, Valle D,
eds. The metabolic and molecular bases of inherited disease,
7th ed. McGraw-Hill, New York, pp 2103–2159
Kirsch RE, Meissner PN, Hift RJ (1998) Variegate porphyria.
Semin Liver Dis 18:33–41
Kuhnel A, Gross U, Doss MO (2000) Hereditary copropor-
phyria in Germany: clinical-biochemical studies in 53 pa-
tients. Clin Biochem 33:465–473
Lamoril J, Deybach JC, Puy H, Grandchamp B, Nordmann Y
(1997) Two novel mutations in the coproporphyrinogen
oxidase gene. Hum Mutat 9:78–80
Lamoril J, Martasek P, Deybach JC, Da Silva V, Grandchamp
B, Nordmann Y (1995) A molecular defect in copropor-
phyrinogen oxidase gene causing harderoporphyria, a var-
iant form of hereditary coproporphyria. Hum Mol Genet 4:
275–278
Lamoril J, Puy H, Gouya L, Rosipal R, Da Silva V, Grand-
champ B, Foint T, Bader-Meunier B, Dommergues JP, Dey-
bach JC, Nordmann Y (1998) Neonatal hemolytic anemia
due to inherited harderoporphyria: clinical characteristics
and molecular basis. Blood 91:1453–1457
Lockwood WH, Poulos V, Rossi E, Curnow DH (1985) Rapid
procedure for fecal porphyrin assay. Clin Chem 31:1163–
1167
Long C, Smyth SJ, Woolf J, Murphy GM, Finlay AY, New-
combe RG, Elder GH (1993) The detection of latent vari-
egate porphyria by fluorescence emission spectroscopy of
plasma. Br J Dermatol 129:9–13
Martasek P (1998) Hereditary coproporphyria. Semin Liver
Dis 18:25–32
Martasek P, Camadro JM, Delfau-Larue MH, Dumas JB,
Montagne JJ, De Verneuil H, Labbe P, Grandchamp B
(1994a) Molecular cloning sequencing and functional ex-
pression of a cDNA encoding human coproporphyrinogen
oxidase. Proc Natl Acad Sci USA 91:3024–3028
Martasek P, Camadro JM, Raman CS, Lecomte MC, Le Caer
JP, Demeler B, Grandchamp B, Labbe P (1997) Human co-
proporphyrinogen oxidase: biochemical characterization of
recombinant normal and R231W mutated enzymes ex-
pressed in E. coli as soluble, catalytically active homodimers.
Cell Mol Biol (Noisy-le-grand) 43:47–58
Martasek P, Nordmann Y, Grandchamp B (1994b) Homozy-
gous hereditary coproporphyria caused by an arginine to
tryptophan substitution in coproporphyrinogen oxidase and
common intragenic polymorphisms. Hum Mol Genet 3:
477–480
Nordmann Y, Deybach JC (1990) Human hereditary por-
phyrias. In: Dailey HA, ed. Biosynthesis of heme and chlo-
rophylls. McGraw-Hill, New York pp 491–542
Nordmann Y, Grandchamp B, de Verneuil H, Phung L, Car-
tigny B, Fontaine G (1983) Harderoporphyria: a variant
hereditary coproporphyria. J Clin Invest 72:1139–1149
Poh-Fitzpatrick MB (1980) A plasma porphyrin fluorescence
marker for variegate porphyria. Arch Dermatol 116:
543–547
Puy H, Deybach JC, Lamoril J, Robreau AM, Da Silva V,
Gouya L, Grandchamp B, Nordmann Y (1997) Molecular
epidemiology and diagnosis of PBG deaminase gene defects
in acute intermittent porphyria. Am J Hum Genet 60:
1373–1383
Roberts AG, Puy H, Dailey TA, Morgan RR, Whatley SD,
Dailey HA, Martasek P, Nordmann Y, Deybach JC, Elder
GH (1998). Molecular characterisation of homozygous var-
iegate porphyria. Hum Mol Genet 7:1921–1925
Rosipal R, Lamoril J, Puy H, Da Silva V, Gouya L, De Rooij
FWM, Te Velde K, Nordmann Y, Martasek P, Deybach JC
(1999) Systematic analysis of coproporphyrinogen oxidase
gene defects in hereditary coproporphyria and mutation up-
date. Hum Mut 13:44–53
Schreiber WE, Zhang X, Senz J, Jamani A (1997) Hereditary
coproporphyria: exon screening by heteroduplex analysis
detects two novel mutations in the coproporphyrinogen
oxidase gene. Hum Mutat 10:196–200
Susa S, Daimon M, Yamamori I, Kondo M, Yamatani K, Sasaki
H, Kato T (1998) A novel mutation of coproporphyrinogen
oxidase (CPO) gene in a Japanese family. J Hum Genet 43:
182–184
Taketani S, Kohno H, Furukawa T, Yoshinaga T, Tokunaga R
(1994) Molecular cloning, sequencing and expression of
cDNA encoding human coproporphyrinogen oxidase.
Biochim Biophys Acta 1183:547–549
Thompson JD, Higgins DG, Gibson TJ (1994) Clustal W im-
proving the sensitivity of progressive multiple sequence
alignment through sequence weighting, position-specific gap
penalties and weight matrix choice. Nucleic Acids Res 22:
4673–4680
Whatley SD, Puy H, Morgan RR, Robreau AM, Roberts AG,
Nordmann Y, Elder GH, Deybach JC (1999a) Variegate por-
phyria in Western Europe: identification of PPOX gene mu-
tations in 104 families, extent allelic heterogeneity, and
absence of correlation between phenotype and type of mu-
tation. Am J Hum Genet 65:984–994
Whatley SD, Woolf JR, Elder GH (1999b) Comparison of
complementary and genomic DNA sequencing for the de-
tection of mutations in the HMBS gene in British patients
with acute intermittent porphyria: identification of twenty-
five novel mutations. Hum Genet 104:505–510
